Navigation Links
UCSF teams tackle childhood mortality and river blindness
Date:1/10/2013

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

An international team led by Thomas M. Lietman, MD, associate director of the UCSF Francis I. Proctor Foundation for Research in Ophthalmology, received $12 million for a multi-year trial to study the effectiveness of mass oral administration of the antibiotic azithromycin in reducing childhood mortality in Niger, Tanzania and Malawi three nations with severe childhood mortality rates.

A second team, led by James H. McKerrow, MD, PhD, professor of pathology and pharmaceutical chemistry, received $4.3 million to identify and develop a drug that kills the parasitic roundworms known as filiariae that cause river blindness, the leading cause of blindness in parts of West Africa.

If successfully developed, the same drug will have a high probability of killing the closely related parasite that causes lymphatic filariasis, or elephantiasis, a crippling and disfiguring disease that affects millions of people in Africa, Asia, the Indian subcontinent and South America.

Expanding Prevention of Child Mortality

Lietman's project is based on an earlier study in which communities in Ethiopia that received mass doses of azithromycin to treat trachoma a strain of chlamydia that causes blindness experienced an overall reduction in childhood mortality from all causes.

"Now we need to see whether that effect can be replicated in areas that don't have a lot of trachoma," said Lietman, a UCSF professor in the departments of Ophthalmology and Epidemiology & Biostatistics. "If we want to make a public health difference, we have to show that we can reduce childhood mortality in areas that are not otherwise receiving mass antibiotics."

Community-wide antibiotic administration is common in African nations where trachoma is usually found, he said.

Preschool children in Lietman's study will be randomized to receive either a cherry-flavored oral suspension of azithromycin or a placebo every six months for two years. If there is a significant reduction in mortality in the communities that receive the antibiotic, the study will be extended for another two years and all communities will receive antibiotics.

Lietman and his team will closely monitor for development of antibiotic resistant diseases in the communities treated with azithromycin. "It's a complicated question," he said. "We think we will select for antibiotic resistance. However, many of us believe that might be a price worth paying if there is truly a reduction in childhood mortality."

Lietman noted two mitigating factors with regard to antibiotic resistance. In communities treated with azithromycin for trachoma, resistance to the antibiotic gradually disappears over the two years after such treatments stop. In addition, he said, azithromycin belongs to a class of antibiotic that is rarely used in sub-Saharan Africa, so even if an infection is resistant to azithromycin, it could still be treatable by one of six other classes of antibiotics.

Finding New Drugs for Parasitic Disease

The goal of McKerrow's study is to find a drug that kills the adult form of the parasitic filarial worm, which is spread by a fly that breeds near fast-flowing rivers.

When the fly bites, it deposits larvae under the skin that grow into worms several inches long. The parasite associated with river blindness attacks the eye, while its relative that is responsible for lymphatic filariasis blocks the lymphatic channels in the groin, resulting in extreme swelling of the lower extremities.

McKerrow's research group will employ new software developed by UCSF research specialist Chris Marcellino that significantly speeds the screening of potential compounds. Conventional drug screening technology uses plates with many hollows, or wells, each of which contains a candidate compound that is screened individually for promising activity. The new software allows an entire plate to be scanned for results in seconds. Scanning and evaluating a whole plate rather than individual wells is necessary, McKerrow explained, because of the large size of the worms, which restrict each plate to dozens rather than hundreds of wells.

"With conventional, well-by-well scanning, it would take a long time to screen many compounds," said McKerrow. "But if you can scan a whole plate and then move on to the next plate in a few seconds, you can filter through thousands of compounds much more efficiently."

The compounds will come from two sources. The first is what McKerrow calls traditional drug discovery, which starts from chemicals that aren't yet drugs. That research will take advantage of unique chemistry developed by Bay Area biotech company Anacor Pharmaceuticals. The second source is "repurposed drugs" that have already been approved by the FDA for human use. Working in collaboration with the UCSF Small Molecule Discovery Center, McKerrow's group expects to create a library of approximately 1,700 FDA-approved drugs that can be used in this and similar screens.

Based on earlier research, the team already has identified a promising possibility: auranofin, a drug used for decades to treat rheumatoid arthritis, which has proven effective in animal models of filariasis. McKerrow said he expects to have one or two clinical candidates drugs that are ready for final FDA testing and potential approval in three years.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms
2. FORMA Therapeutics teams with TGen Drug Development
3. Home-Based Care Teams Offer Help for Those With Dementia
4. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
5. Teams Boost Wellness Challenge Results Without Incentives According to New Health Enhancement Systems White Paper
6. AGNITY Healthcare Teams with Alcatel-Lucent to Deliver Innovative Mobile Healthcare Solutions over 4G LTE Mobile Networks
7. Centre for Global Non-Communicable Diseases launched to tackle killer diseases
8. New drug to tackle fat problems
9. Former Vikings and NFL Greats Tackle Sleep Apnea at Upcoming Minneapolis Event
10. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
11. Keystone Symposia announces new 3-year grant to tackle major global health challenges
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF teams tackle childhood mortality and river blindness
(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor , ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable design, ... Line of Model Homes . Independently, Ecocor and RPA have extensive experience with ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... inaugural SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student ... MS in Educational Leadership and Administration at St. Thomas University in Miami, Florida, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... “Letters From Home”: a moving compilation of letters that ... God. “Letters From Home” is the creation of published author, John Allred, a passionate ... Jerry Savelle Ministries International, who has traveled and ministered on four continents. , “It ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
Breaking Medicine Technology: